Table 5.
Mean annual exacerbation rate by asthma therapy
| Age, years | ICSa | ICS/LABA | LTRA | OCS | ||||
|---|---|---|---|---|---|---|---|---|
| n | Mean exacerbation rate (SD) | n | Mean exacerbation rate (SD) | n | Mean exacerbation rate (SD) | n | Mean exacerbation rate (SD) | |
| Females | ||||||||
| 0 -1 | 2017 | 1.50 (0.89) | 5 | 1.60 (0.89) | 490 | 1.67 (1.07) | 3502 | 1.42 (0.83) |
| >1 – 2 | 2036 | 1.49 (0.89) | 10 | 2.0 (2.0) | 1060 | 1.59 (1.08) | 3709 | 1.37 (0.74) |
| >2 – 3 | 2084 | 1.46 (0.86) | 17 | 1.35 (0.79) | 1440 | 1.56 (1.0) | 3289 | 1.34 (0.77) |
| 4 – 12 | 11321 | 1.36 (0.83) | 2034 | 1.42 (0.93) | 12209 | 1.44 (0.89) | 20719 | 1.29 (0.81) |
| 13 – 17 | 3693 | 1.35 (0.93) | 3227 | 1.42 (0.93) | 5915 | 1.45 (1.06) | 11070 | 1.39 (1.01) |
| Overall 0-17 | 21151 | 1.40 (0.86) | 5293 | 1.42 (0.93) | 21114 | 1.46 (0.96) | 42289 | 1.34 (0.86) |
| Males | ||||||||
| 0–1 | 4552 | 1.60 (1.02) | 6 | 2.0 (0.63) | 1232 | 1.68 (1.09) | 6112 | 1.47 (0.89) |
| >1–2 | 3950 | 1.52 (0.94) | 22 | 1.91 (1.06) | 2042 | 1.65 (1.08) | 5803 | 1.42 (0.81) |
| >2–3 | 3630 | 1.48 (0.93) | 40 | 1.93 (1.46) | 2446 | 1.56 (1.02) | 5114 | 1.40 (0.89) |
| 4–12 | 19133 | 1.39 (0.84) | 3743 | 1.42 (0.84) | 21698 | 1.45 (0.92) | 32895 | 1.32 (0.84) |
| 13–17 | 4208 | 1.32 (0.85) | 3777 | 1.37 (0.91) | 21698 | 1.45 (0.92) | 13397 | 1.35 (0.92) |
| Overall 0–17 | 35473 | 1.43 (0.89) | 7588 | 1.40 (0.88) | 34104 | 1.45 (1.06) | 42289 | 1.34 (0.86) |
aincludes nebulized medications
ICS inhaled corticosteroid, LABA long-acting beta agonist, LTRA leukotriene receptor antagonist, OCS oral corticosteroid